MCQs-Autacoids and Related Drugs part 5 I Pharmacology KD Tripathi mcqs part 14

14.1 Which of the following is a reserve drug but not a disease modifying drug in rheumatoid arthritis:

A. Chloroquine

B. Sulfasalazine

C. Prednisolone

D. Methotrexate

14.2 Choose the correct statement about use of gold sod. thiomalate in rheumatoid arthritis:

A. It affords more rapid symptomatic relief than NSAIDs

B. The NSAIDs therapy is discontinued when it is started

C. It is used as an alternative to corticosteroids

D. It is used only in severe cases when other diseases modifying antirheumatic drugs have failed

14.3 Choose the correct statement(s) about auranofin:

A. It is an orally active gold compound

B. It is equally effective but less toxic than

injected gold-sodium-thiomalate

C. Its major adverse effect is dermatitis

D. All of the above are correct

14.4 Used as a remission inducing agent in rheumatoid arthritis, hydroxychloroquine:

A. Is more effective than chloroquine

B. Produces a lower incidence of retinal damage than chloroquine

C. Is more effective and more toxic than gold

D. Both ‘A’ and ‘B’ are correct

14.5 Sulfasalazine is used in the following disease(s):

A. Bacillary dysentery

B. Ulcerative colitis

C. Rheumatoid arthritis

D. Both ‘B’ and ‘C’ are correct

14.6 Disease modifying antirheumatic drugs are indicated

in rheumatoid arthritis:

A. In place of NSAIDs in patients who donot tolerate the latter

B. Along with NSAIDs in patients with progressive disease

C. Only when NSAIDs fail to afford symptomatic relief

D. In all patients irrespective of disease status/ concurrent medication 

14.7 What is true of disease modifying antirheumatic drugs:

A. Their beneficial effect is manifest only after 1-3 months of therapy

B. The disease does not recurr once they induce remission

C. They are to be used life long

D. Concurrent use of more than one disease modifying drug is not recommended

14.8 The following antirheumatic drug affords symptomatic relief but does not bring about remission in rheumatoid arthritis:

A. Gold sodium thiomalate

B. Prednisolone

C. Hydroxychloroquine

D. Leflunomide

14.9 Which of the following is a disease modifying antirheumatic drug whose active metabolite inhibits the enzyme dihydro-orotate dehydrogenase:

A. Leflunomide

B. Nimesulide

C. Sulfasalazine

D. Colchicine

14.10 Which component of sulfasalazine is responsible for

the therapeutic effect in rheumatoid arthritis:

A. Intact sulfasalazine molecule

B. Sulfapyridine

C. 5–aminosalicylic acid

D. Both ‘B’ and ‘C’ 

14.11 Among the disease modifying antirheumatic drugs, fastest symptom relief is obtained with:

A. Auranofin

B. Hydroxychloroquine

C. Sulfasalazine

D. Methotrexate

14.12 Hyperuricaemia is produced by the following drugs except:

A. Ethambutol

B. Pyrazinamide

C. Sulfinpyrazone

D. Hydrochlorothiazide

14.13 Select the first choice drug for acute gout:

A. Cochicine

B. Indomethacin

C. Allopurinol

D. Dexamethasone

14.14 Nonsteroidal antiinflammatory drugs are more commonly used than colchicine in acute gout because:

A. They are more effective

B. They act more rapidly

C. They have additional uricosuric action

D. They are better tolerated 

14.15 Select the drug which is neither analgesic, nor anti inflammatory, nor uricosuric, but is highly efficacious in acute gout:

A. Prednisolone

B. Colchicine

C. Naproxen

D. Sulfinpyrazone

14.16 The most important dose limiting adverse effect of colchicine is:

A. Sedation

B. Kidney damage

C. Diarrhoea

D. Muscle paralysis

14.17 Probenecid has the following action(s):

A. Uricosuric

B. Analgesic

C. Antiinflammatory

D. Both ‘A’ and ‘C’

14.18 Select the drug which is used in chronic gout but is not uricosuric:

A. Probenecid

B. Phenylbutazone

C. Sulfinpyrazone

D. Allopurinol

14.19 Sulfinpyrazone has the following action(s):

A. Antiplatelet aggregatory

B. Uricosuric

C. Antiinflammatory

D. Both ‘A’ and ‘B’

14.20 Allopurinol lowers the plasma concentration of:

A. Hypoxanthine

B. Xanthine

C. Uric acid

D. All of the above

14.21 Choose the correct statement about allopurinol:

A. It is a purine antimetabolite with antineoplastic activity

B. It is a competitive inhibitor of xanthine oxidase

C. It is inactive itself, but its metabolite alloxanthine is a competitive inhibitor of xanthine oxidase

D. Both allopurinol as well as its metabolite alloxanthine are noncompetitive inhibitors of xanthine oxidase

14.22 Allopurinol does not inhibit the metabolism of:

A. 6-Mercaptopurine

B. 6-Thioguanine

C. Azathioprine

D. Theophylline

14.23 A 35-year-old male presented with an attack of acute gout. He was treated with a 10 day course of

naproxen. His blood uric acid level is high. What future line of treatment is most appropriate:

A. No regular medication. Treat attacks of acute gout when they occur with naproxen.

B. Regular long-term treatment with naproxen

C. Regular long-term treatment with allopurinol

D. Start with allopurinol + naproxen for 2 months followed by long-term allopurinol treatment

14.24 Allopurinol is indicated in the following category of chronic gout patients:

A. Over producers of uric acid

B. Under excretors of uric acid

C. Those with tophi and/or renal urate stones

D. All of the above

14.25 Allopurinol has a therapeutic effect in the following conditions except:

A. Radiotherapy induced hyperuricaemia

B. Hydrochlorothiazide induced hyperuricaemia

C. Acute gouty arthritis

D. Kala-azar

14.1 C 14.2 D 14.3 A 14.4 B 14.5 D 14.6 B 14.7 A 14.8 B 14.9 A 14.10 B 14.11 D 14.12 C 14.13 B 14.14 D 14.15 B 14.16 C 14.17 A 14.18 D 14.19 D 14.20 C 14.21 B 14.22 B 14.23 D 14.24 D 14.25 C